Cardio-cerebrovascular disease and Helicobacter pylori-related metabolic syndrome: We consider eradication therapy as a potential cardio-cerebrovascular prevention strategy.

[1]  J. Kountouras,et al.  Helicobacter pylori‐related chronic hepatitis C infection and the risk for cardiovascular disease , 2017, Liver international (Print).

[2]  G. Faggian,et al.  Coronary artery disease and Helicobacter pylori infection: Should we consider eradication therapy as cardiovascular prevention strategy? , 2016, International journal of cardiology.

[3]  Chi-Hsiang Chung,et al.  Atrial fibrillation, liver disease, antithrombotics and risk of cerebrovascular events: A population-based cohort study. , 2016, International journal of cardiology.

[4]  K. Lee,et al.  Impact of Cadmium Exposure on the Association between Lipopolysaccharide and Metabolic Syndrome , 2015, International journal of environmental research and public health.

[5]  Antonio Gasbarrini,et al.  Extragastric Diseases and Helicobacter pylori , 2013, Helicobacter.

[6]  Jannis Kountouras,et al.  Helicobacter pylori might contribute to nonalcoholic fatty liver disease–related cardiovascular events by releasing prothrombotic and proinflammatory factors , 2014, Hepatology.

[7]  J. Kountouras,et al.  Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. , 2013, Metabolism: clinical and experimental.

[8]  J. Kountouras,et al.  Helicobacter pylori infection and the risk for cardiovascular disease. , 2011, European journal of internal medicine.

[9]  Jannis Kountouras,et al.  The Association Between Helicobacter pylori Infection and Insulin Resistance: A Systematic Review , 2011, Helicobacter.

[10]  J. Konturek,et al.  Helicobacter pylori infection in coronary artery disease. , 2006, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.